Expert hematologist/oncologists highlight recent advances in the treatment of advanced RCC and consider their impact on clinical practice.
EP. 1: Overview of the Treatment Landscape in Advanced Clear Cell RCC
Expert hematologist/oncologist Brian Rini, MD, spearheads a comprehensive discussion on the broad treatment landscape for advanced clear cell renal cell carcinoma.
EP. 2: First-Line Treatment for Advanced RCC: Lenvatinib + Pembrolizumab
Centering discussion around the combination of lenvatinib + pembrolizumab in advanced clear cell RCC, Hans Hammers, MD, considers the role of this combination regimen in the first-line treatment setting.
EP. 3: First-Line Treatment for Advanced RCC: Cabozantinib + Nivolumab
Sumanta Pal, MD, an expert hematologist/oncologist, evaluates the combination of cabozantinib + nivolumab as first-line therapy for advanced clear cell renal cell carcinoma.
EP. 4: Optimizing Dosing of First-Line IO-TKI Therapy in Advanced RCC
Shared insight on optimal dosing strategies with first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced clear cell renal cell carcinoma.
EP. 5: First-Line Treatment in Advanced RCC: Quality of Life Considerations
Expert panelists consider the importance of quality of life when selecting first-line treatment regimens for patients with advanced clear cell renal cell carcinoma.
EP. 6: First-Line Treatment in Advanced RCC: Sequencing Therapy
Focused discussion on the selection of first-line therapy for advanced clear cell renal cell carcinoma based on sites of metastasis.
EP. 7: Adjuvant Immunotherapy in Advanced Renal Cell Carcinoma
Expert hematologist/oncologists consider the potential role for adjuvant immunotherapy in patients with advanced clear cell renal cell carcinoma.
EP. 8: Selecting Treatment for Advanced RCC in Second Line and Beyond
Panelists identify second-line treatment options they would consider in advanced clear cell RCC if a patient progresses following first-line therapy.
EP. 9: Triplet Regimens in Advanced RCC in the Frontline Setting
Shared insight on the data from the COSMIC-313 trial and the potential for first-line triplet regimens in patients with advanced clear cell renal cell carcinoma.
EP. 10: First-Line Treatment for Advanced Clear Cell RCC: Key Takeaways
Closing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.
2 Clarke Drive Cranbury, NJ 08512